Table 1.
Baseline demographics and clinical characteristics
| Characteristic | VCO (n = 185) | VPO (n = 76) | VOB (n = 47) | VO (n = 298) |
|---|---|---|---|---|
| Age (years) | 63.2 ± 12.6 | 62.5 ± 11.3 | 65.3 ± 12.4 | 61.7 ± 13.5 |
| Sex | ||||
| Female | 75 (40.5) | 28 (36.8) | 22 (46.8) | 119 (39.9) |
| Male | 110 (59.5) | 48 (63.2) | 25 (53.2) | 179 (60.1) |
| Duration of MF (years) | 5.2 ± 6.3 | 5.2 ± 6.0 | 4.3 ± 4.1 | 5.5 ± 6.8 |
| Months from diagnosis to enrollment, mean (minimum; maximum) | 36.6 (0.9; 210.2) | 34.2 (0.9; 140.7) | 42.6 (1.9; 210.2) | 35.8 (0.6; 210.2) |
| TNMB classification | ||||
| IA | 60 (32.4) | 21 (27.6) | 7 (14.9) | 105 (35.2) |
| IB | 49 (26.5) | 27 (35.5) | 12 (25.5) | 75 (25.2) |
| IIA | 1 (0.5) | 3 (3.9) | 2 (4.3) | 6 (2.0) |
| IIB | 11 (5.9) | 5 (6.6) | 6 (12.8) | 15 (5.0) |
| III–IV | 6 (3.2) | 3 (3.9) | 6 (12.8) | 10 (3.4) |
| Missing/unknown | 58 (31.4) | 17 (22.4) | 14 (29.8) | 87 (29.2) |
Data are presented as mean ± standard deviation or n (%) unless otherwise indicated
MF mycosis fungoides cutaneous T-cell lymphoma, TNMB tumor-node-metastasis-blood, VCO chlormethine gel + topical corticosteroids + any other treatment, VO chlormethine gel + any other treatment, VOB chlormethine + oral bexarotene + other, VPO chlormethine + phototherapy + other